Findings from Eli Lilly and Company Broaden Understanding of Type 2 Diabetes (Reduction of Prevalence of Patients Meeting the Criteria for Metabolic Syndrome With Tirzepatide: a Post Hoc Analysis From the Surpass Clinical Trial Program).

Předmět:
Zdroj: Diabetes Week; 3/11/2024, p282-282, 1p
Abstrakt: A recent study conducted by Eli Lilly and Company has found that tirzepatide, a medication used to treat type 2 diabetes and obesity, can reduce the prevalence of metabolic syndrome in patients. Metabolic syndrome is a condition characterized by a combination of cardiovascular risk factors such as insulin resistance, obesity, and high blood pressure. The study showed that tirzepatide was more effective than other medications in reducing the prevalence of metabolic syndrome and its individual components. These findings suggest that tirzepatide may have potential benefits for improving cardiovascular health in individuals with type 2 diabetes. [Extracted from the article]
Databáze: Complementary Index